Table 2.
Post-transplant outcomes in solid organ transplant recipients consenting to the STCS
| N (%) | Total (5249) |
Kidney* (2972, 56.5%) |
Liver (1164, 22.2%) |
Lung (470, 9.0%) |
Heart (397, 7.6%) |
Other (246, 4.7%) |
| Follow-up time (years), median (IQR) | 4.4 (1.9–7.6) | 4.8 (2.2–8) | 3.7 (1.4–6.9) | 3.8 (1.7–6.6) | 3.9 (1.5–7.4) | 5.7 (2.4–8.3) |
| Patient and allograft survival | ||||||
| Deaths, N (%) | 808 (15.4) | 314 (10.6) | 208 (17.9) | 173 (36.8) | 75 (18.9) | 38 (15.4) |
| Time to death (years), median (IQR) | 2 (1–5) | 3.5 (1.2–6) | 1.3 (0.2–3.6) | 2.9 (1.1–4.7) | 0.3 (0–3) | 3.5 (0.9–6.8) |
| Patients with graft failure (GF) in first TX, N (%) | 538 (10.2) | 243 (8.2) | 124 (10.7) | 84 (17.9) | 34 (8.6) | 53 (21.5) |
| Time to first GF (years), median (IQR) | 1.1 (0.1–3.8) | 1.8 (0.2–4.8) | 0.3 (0–1.7) | 2.9 (1.2–4.6) | 0 (0–0.1) | 0.9 (0–3.2) |
| Re-TX† after first GF, N (% of GF) | 184 (34.2) | 60 (24.7) | 84 (67.7) | 17 (20.2) | 4 (11.8) | 19 (35.8) |
| Post-transplant infectious diseases (ID) | ||||||
| Patients with any ppv‡ ID episode, N (%) | 3387 (64.5) | 1920 (64.6) | 684 (58.8) | 325 (69.1) | 273 (68.8) | 185 (75.2) |
| Average number of episodes, median (IQR) | 3 (2–6) | 3 (2–5) | 3 (1–5) | 5 (2–9) | 3 (2–5) | 3 (2–6) |
| Time to first episode (days), median (IQR) | 59 (13–240) | 82 (23–312) | 23 (8–158) | 43 (8–149) | 32 (8–208) | 33 (9–198) |
| Post-transplant cancer | ||||||
| Patients with any cancer, N (%) | 978 (18.6%) | 569 (19.1) | 207 (17.8) | 99 (21.1) | 60 (15.1) | 43 (17.5) |
| PTLD, N (% of cancer) | 68 (7) | 29 (5.1) | 19 (9.2) | 12 (12.1) | 4 (6.7) | 4 (9.3) |
| Any skin cancer, N (% of cancer) | 654 (66.9) | 423 (74.3) | 81 (39.1) | 65 (65.7) | 53 (88.3) | 32 (74.4) |
| Rejections | ||||||
| Patients with any rejection in first TX, N (%) | 2006 (38.2) | 982 (33) | 373 (32%) | 263 (56) | 327 (82.4) | 61 (24.8) |
| Within 1 year, N (% of rejection) | 1616 (80.6) | 788 (80.2) | 294 (78.8) | 191 (72.6) | 300 (91.7) | 43 (70.5) |
| Time to first rejection (days), median (IQR) | 76 (15–245) | 97 (15–250) | 66 (12–290) | 84 (24–371) | 18 (12–58) | 62 (19–523) |
*Kidney TX also includes transplants with double kidney.
†A re-TX is a TX with the same allograft that has been transplanted and lost before.
‡proven, probable or viral syndrome.
GF, graft failure; IQR, interquartile range; PTLD, post-transplant lymphoproliferative disorders; STCS, Swiss Transplant Cohort Study; TX, transplantation.